3pp0 › Citations

Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.

Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S
J Biol Chem 286 18756-65 (2011)
Cited: 220 times
EuropePMC logo PMID: 21454582

Abstract

Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis. Small molecule kinase inhibitors of EGFR and of both HER2 and EGFR have received approval for the treatment of cancer. We present the first high resolution crystal structure of the kinase domain of HER2 in complex with a selective inhibitor to understand protein activation, inhibition, and function at the molecular level. HER2 kinase domain crystallizes as a dimer and suggests evidence for an allosteric mechanism of activation comparable with previously reported activation mechanisms for EGFR and HER4. A unique Gly-rich region in HER2 following the α-helix C is responsible for increased conformational flexibility within the active site and could explain the low intrinsic catalytic activity previously reported for HER2. In addition, we solved the crystal structure of the kinase domain of EGFR in complex with a HER2/EGFR dual inhibitor (TAK-285). Comparison with previously reported inactive and active EGFR kinase domain structures gave insight into the mechanism of HER2 and EGFR inhibition and may help guide the design and development of new cancer drugs with improved potency and selectivity.

Reviews - 3pp0 mentioned but not cited (4)

  1. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J. Cancers (Basel) 11 (2019)
  2. Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers. Gajdosova V, Lorencova L, Kasak P, Tkac J. Sensors (Basel) 20 E4022 (2020)
  3. Acridine as an Anti-Tumour Agent: A Critical Review. Varakumar P, Rajagopal K, Aparna B, Raman K, Byran G, Gonçalves Lima CM, Rashid S, Nafady MH, Emran TB, Wybraniec S. Molecules 28 193 (2022)
  4. The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib. Yang LL, Luo XZ, Xie LL, Lei XZ, Zhu J. Transl Cancer Res 12 2197-2211 (2023)

Articles - 3pp0 mentioned but not cited (111)



Reviews citing this publication (17)

  1. The structural basis for control of eukaryotic protein kinases. Endicott JA, Noble ME, Johnson LN. Annu Rev Biochem 81 587-613 (2012)
  2. A structural perspective on the regulation of the epidermal growth factor receptor. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. Annu Rev Biochem 84 739-764 (2015)
  3. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Roskoski R. Pharmacol Res 87 42-59 (2014)
  4. Structural Basis for the Non-catalytic Functions of Protein Kinases. Kung JE, Jura N. Structure 24 7-24 (2016)
  5. Regulation of the catalytic activity of the EGF receptor. Endres NF, Engel K, Das R, Kovacs E, Kuriyan J. Curr Opin Struct Biol 21 777-784 (2011)
  6. αC helix displacement as a general approach for allosteric modulation of protein kinases. Palmieri L, Rastelli G. Drug Discov Today 18 407-414 (2013)
  7. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Schroeder RL, Stevens CL, Sridhar J. Molecules 19 15196-15212 (2014)
  8. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Garrido-Castro AC, Felip E. Transl Lung Cancer Res 2 122-127 (2013)
  9. Quantification of HER family receptors in breast cancer. Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Breast Cancer Res 17 53 (2015)
  10. Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. Fischer PM. Med Res Rev 37 314-367 (2017)
  11. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes. Hart V, Gautrey H, Kirby J, Tyson-Capper A. Oncotarget 11 4338-4357 (2020)
  12. Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. Lategahn J, Keul M, Rauh D. Angew Chem Int Ed Engl 57 2307-2313 (2018)
  13. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Milik SN, Lasheen DS, Serya RAT, Abouzid KAM. Eur J Med Chem 142 131-151 (2017)
  14. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. Najjar MK, Manore SG, Regua AT, Lo HW. Genes (Basel) 13 2065 (2022)
  15. Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges. Bansal I, Pandey AK, Ruwali M. Front Pharmacol 14 1244597 (2023)
  16. Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). Șandor A, Ionuț I, Marc G, Oniga I, Eniu D, Oniga O. Pharmaceuticals (Basel) 16 534 (2023)
  17. Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB. Fu XH, Li J, Huang JJ, Zheng S, Zhang SZ. Cancer Chemother Pharmacol 68 1373-1376 (2011)

Articles citing this publication (88)



Quick links